tumor suppression

Product Purpose:

• Selective Anticancer Activity: Induces necrosis in a variety of cancer cell lines, including pancreatic, breast, ovarian, cervical, and leukemia cells, while sparing normal cells like fibroblasts and lymphocytes, due to its specific binding to HDM-2 on cancer cell membranes.

• Broad-Spectrum Efficacy: Effective against both solid tumors (e.g., pancreatic, colon, lung) and non-solid tumors (e.g., acute myeloid leukemia), including p53-null cells, broadening its potential therapeutic scope.

• Rapid Action: Causes cancer cell lysis within minutes to hours by forming transmembrane pores, offering a faster mechanism of action compared to apoptosis-based therapies.

• Synergistic Potential: Enhances the efficacy of other anticancer agents, such as paclitaxel and methotrexate, by reducing their IC50 values, potentially improving outcomes in combination therapies.

• Tumor Suppression in Vivo: Demonstrates tumor eradication in animal models, such as nude mice with pancreatic cancer xenografts, without significant toxicity to healthy tissues.

• Potential for Targeted Delivery: When conjugated to nanoparticles (e.g., single-walled carbon nanotubes), PNC-27 enhances focal accumulation in cancer tissue, improving therapeutic outcomes in models like colon adenocarcinoma.

Research Use Only:

PNC-27 is intended strictly for in vitro testing and laboratory experimentation. It’s not intended for human or animal medical use. It’s not a drug, food, or cosmetic and should not be misbranded, misused, or mislabeled as such.